Good news seems to be on the long-term horizon. The problem is the time it takes to adequately test dosage. Ten patients isn't going to cut the mustard and get this product into Phase III for several years. I have seen this scenario happen with other companies. Stocks get ruined because the companies are more interested in trying to perfect dosage than to take a positive dosage and navigate it through advanced trials. APTOF is a prime example of that type of history.
Market Data 
Markets 
AI
